ArticleTheranostics2022
Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1.
Article in Theranostics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 91 citations in OpenAlex.
- Treg-derived exosomal miR-146a orchestrates bidirectional Treg-CAF crosstalk to sustain immunosuppressive tumor microenvironments.Medical oncology (Northwood, London, England) · 2026Review
- Cisplatin-Induced Rab27A/B Exosomal PD-L1 Axis Suppresses Antitumor Immunity and Correlates with Poor 5-Year Survival in Lung Squamous Cell Carcinoma and Adenocarcinoma.Current issues in molecular biology · 2026Article
- Adaptive therapy: a balanced triangle for chronic cancer management.Journal of the National Cancer Center · 2026Article
- Perineural invasion in digestive tract tumors: Immune system interactions and therapeutic strategies.World journal of clinical oncology · 2026Review
- Nuclear gasdermin E drives endothelin-1-induced metastatic progression independently of the pyroptosis.Cell death & disease · 2026Article
- PD‑L1 deficient exosomes derived from lung cancer cell line enhances NK cell‑mediated anti‑tumor immunity against lung cancer.Cell communication and signaling : CCS · 2026Article
- The role and prospects of extracellular vesicles in advanced drug and vaccine delivery.Frontiers in immunology · 2026Review
- In vivo optoacoustic imaging of endothelin receptor expression and treatment response in the hypoxic tumor microenvironment.European journal of nuclear medicine and molecular imaging · 2026Article
- An updated review on the role of extracellular vesicles in immune system modulation in breast cancer with special emphasis on immune checkpoint regulators.Frontiers in immunology · 2026Review
- LSD1 inhibition sensitizes anti-PD1 blockade immunotherapy by inhibiting the long-range attack of tumor-derived extracellular vesicles.Acta pharmaceutica Sinica. B · 2025Article
- The potential of extracellular vesicle-derived nanosystems in precision oncology.Nanomedicine (London, England) · 2025Article
- CXCL12-targeting siRNA nanoparticles alleviate immunosuppression and inhibit tumor progression in esophageal squamous cell carcinoma.Journal of nanobiotechnology · 2025Article
- Utilization of exosome-based therapies to augment anti-PD-1/PD-L1 therapies.Journal for immunotherapy of cancer · 2025Review
- Exosome-Mediated Cellular Communication in the Tumor Microenvironment Imparts Drug Resistance in Breast Cancer.Cancers · 2025Review
- Leveraging nature's nanocarriers: Translating insights from extracellular vesicles to biomimetic synthetic vesicles for biomedical applications.Science advances · 2025Review
- Developing anti-TDE vaccine for sensitizing cancer cells to treatment and metastasis control.NPJ vaccines · 2025Review
- Cancer cell-derived extracellular vesicles: a potential target for overcoming tumor immunotherapy resistance and immune evasion strategies.Frontiers in immunology · 2025Review
- Crosstalk Between Extracellular Vesicles and Regulatory T Cells Across Cancers: From Interaction to Therapeutic Potential.International journal of nanomedicine · 2025Review
- Exosomal PD-L1 detection in cancer predictive biomarker for response to immune checkpoint blockade therapy.Frontiers in immunology · 2025Review
- Dual-Active Nanoimmunomodulators for the Synergistic Enhancement of the Antitumor Efficacy of Photodynamic Immunotherapy.Biomaterials research · 2025Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Extracellular vesicles (EVs) carrying tumor cell-derived programmed death-ligand 1 (PD-L1) interact with programmed death 1 (PD-1)-producing T cells, thus significantly lowering a patient's response to immune checkpoint blockade drugs. No drug that reinvigorates CD8+ T cells by suppressing EV PD-L1 has been approved for clinical usage. Here we have identified macitentan (MAC), an FDA-approved oral drug, as a robust booster of antitumor responses in CD8+ T cells by suppressing tumor cell-derived EV PD-L1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.